Dark Forest Capital Management LP decreased its holdings in shares of Accenture plc (NYSE:ACN – Free Report) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,819 shares of the information technology services provider’s stock after selling 81 shares during the period. Dark Forest Capital Management LP’s holdings in Accenture were worth $640,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Morse Asset Management Inc acquired a new stake in shares of Accenture during the 3rd quarter valued at $25,000. FPC Investment Advisory Inc. lifted its holdings in shares of Accenture by 62.2% during the fourth quarter. FPC Investment Advisory Inc. now owns 73 shares of the information technology services provider’s stock valued at $28,000 after purchasing an additional 28 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Accenture in the 4th quarter valued at $30,000. POM Investment Strategies LLC increased its stake in Accenture by 64.2% in the 4th quarter. POM Investment Strategies LLC now owns 87 shares of the information technology services provider’s stock worth $31,000 after purchasing an additional 34 shares in the last quarter. Finally, Retirement Wealth Solutions LLC purchased a new stake in Accenture during the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 75.14% of the company’s stock.
Insider Buying and Selling
In related news, CAO Melissa A. Burgum sold 232 shares of Accenture stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $394.46, for a total value of $91,514.72. Following the completion of the transaction, the chief accounting officer now directly owns 8,915 shares of the company’s stock, valued at $3,516,610.90. The trade was a 2.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Julie Spellman Sweet sold 2,284 shares of the stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $281.63, for a total transaction of $643,242.92. Following the sale, the chief executive officer now directly owns 9,965 shares in the company, valued at approximately $2,806,442.95. This represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,041 shares of company stock valued at $5,254,956 over the last quarter. Corporate insiders own 0.02% of the company’s stock.
Accenture Stock Up 0.8 %
Accenture (NYSE:ACN – Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The information technology services provider reported $2.82 EPS for the quarter, topping the consensus estimate of $2.81 by $0.01. Accenture had a return on equity of 26.91% and a net margin of 11.41%. The company had revenue of $16.70 billion for the quarter, compared to the consensus estimate of $16.64 billion. During the same period in the previous year, the business posted $2.77 EPS. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, research analysts predict that Accenture plc will post 12.73 EPS for the current year.
Accenture Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Thursday, April 10th will be issued a $1.48 dividend. This represents a $5.92 annualized dividend and a yield of 2.02%. The ex-dividend date of this dividend is Thursday, April 10th. Accenture’s dividend payout ratio (DPR) is presently 48.89%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. UBS Group cut their price target on shares of Accenture from $455.00 to $387.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Guggenheim reduced their target price on Accenture from $400.00 to $395.00 and set a “buy” rating for the company in a report on Friday, March 21st. StockNews.com downgraded Accenture from a “buy” rating to a “hold” rating in a report on Tuesday, March 11th. Morgan Stanley decreased their price objective on Accenture from $380.00 to $372.00 and set an “equal weight” rating for the company in a research report on Monday, March 17th. Finally, Wolfe Research upgraded Accenture from a “peer perform” rating to an “outperform” rating and set a $425.00 target price on the stock in a report on Wednesday, January 8th. Eight investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Accenture currently has an average rating of “Moderate Buy” and an average price target of $377.82.
Get Our Latest Stock Report on ACN
Accenture Company Profile
Accenture plc, a professional services company, provides strategy and consulting, industry X, song, and technology and operation services worldwide. The company offers application services, including agile transformation, DevOps, application modernization, enterprise architecture, software and quality engineering, data management; intelligent automation comprising robotic process automation, natural language processing, and virtual agents; and application management services, as well as software engineering services; strategy and consulting services; data and analytics strategy, data discovery and augmentation, data management and beyond, data democratization, and industrialized solutions comprising turnkey analytics and artificial intelligence (AI) solutions; metaverse; and sustainability services.
Further Reading
- Five stocks we like better than Accenture
- Learn Technical Analysis Skills to Master the Stock Market
- Short Sellers Gave Up on These 3 Names Recently
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Boring Stocks Outperforming the Market This Year
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Accenture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accenture and related companies with MarketBeat.com's FREE daily email newsletter.